Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 7 hours ago
- 1 min read
11/03/2026
UCB announced Phase 3 results of bimekizumab versus Risankizumab in a head-to-head study in PsA (Ref)
UCB announced positive topline results from its Phase 3 BE BOLD/ NCT06624228 head-to-head study, which evaluated BIMZELX®▼(bimekizumab; a selective inhibitor of IL-17A and IL-17F) versus SKYRIZI® (risankizumab; a selective inhibitor of IL-23) for the treatment of adult patients living with active psoriatic arthritis (PsA)
In this study bimekizumab demonstrated statistically significant superiority over risankizumab for the ACR50 primary efficacy endpoint at Week 16
Treatment with bimekizumab was generally well tolerated, with no new safety signals observed through Week 16
BE BOLD was the fourth head-to-head study demonstrated superiority in the bimekizumab clinical trial program across psoriatic disease, and it was the first study conducted in PsA
